These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28301611)

  • 1. GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.
    Esquerré M; Bouillette-Marussig M; Goubier A; Momot M; Gonindard C; Keller H; Navarro A; Bissery MC
    PLoS One; 2017; 12(3):e0174038. PubMed ID: 28301611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.
    Van Damme P; Bouillette-Marussig M; Hens A; De Coster I; Depuydt C; Goubier A; Van Tendeloo V; Cools N; Goossens H; Hercend T; Timmerman B; Bissery MC
    Clin Cancer Res; 2016 Jul; 22(13):3238-48. PubMed ID: 27252412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.
    Soong RS; Song L; Trieu J; Knoff J; He L; Tsai YC; Huh W; Chang YN; Cheng WF; Roden RB; Wu TC; Trimble CL; Hung CF
    Clin Cancer Res; 2014 Nov; 20(21):5456-67. PubMed ID: 24893628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.
    Chuang CM; Monie A; Hung CF; Wu TC
    J Biomed Sci; 2010 Apr; 17(1):32. PubMed ID: 20426849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
    van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
    Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
    Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines.
    Lee SY; Oh JY; Kang TH; Shin HS; Cheng MA; Farmer E; Wu TC; Hung CF
    J Biomed Sci; 2019 May; 26(1):41. PubMed ID: 31133013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of human papillomavirus oncogene-specific CD8 T-cell effector responses in the genital mucosa of vaccinated mice.
    Decrausaz L; Revaz V; Bobst M; Corthésy B; Romero P; Nardelli-Haefliger D
    Int J Cancer; 2010 May; 126(10):2469-78. PubMed ID: 19816937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic HPV Cancer Vaccine Targeted to CD40 Elicits Effective CD8+ T-cell Immunity.
    Yin W; Duluc D; Joo H; Xue Y; Gu C; Wang Z; Wang L; Ouedraogo R; Oxford L; Clark A; Parikh F; Kim-Schulze S; Thompson-Snipes L; Lee SY; Beauregard C; Woo JH; Zurawski S; Sikora AG; Zurawski G; Oh S
    Cancer Immunol Res; 2016 Oct; 4(10):823-834. PubMed ID: 27485136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
    Préville X; Ladant D; Timmerman B; Leclerc C
    Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.